Compare PUMP & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PUMP | DRUG |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Pharmaceuticals and Biotechnology |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 856.4M |
| IPO Year | 2017 | N/A |
| Metric | PUMP | DRUG |
|---|---|---|
| Price | $10.24 | $87.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $12.14 | ★ $104.00 |
| AVG Volume (30 Days) | ★ 1.7M | 278.0K |
| Earning Date | 02-18-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,300,037,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.10 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.51 | $23.18 |
| 52 Week High | $11.66 | $123.75 |
| Indicator | PUMP | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 58.64 | 54.60 |
| Support Level | $9.13 | $85.65 |
| Resistance Level | $10.97 | $92.00 |
| Average True Range (ATR) | 0.50 | 8.78 |
| MACD | 0.10 | -0.36 |
| Stochastic Oscillator | 60.33 | 29.67 |
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.